Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 31;13(1):12382.
doi: 10.1038/s41598-023-39372-3.

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study

Man Yang #  1 , Jiale Sun #  1 , Liqiong Liu #  2   3 , Xiangyi Kong  4 , Dongcai Lin  1 , Hong Zhou  1 , Jidong Gao  5
Affiliations

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study

Man Yang et al. Sci Rep. .

Abstract

Human Epidermal Growth Factor Receptor-2 (HER2)-negative breast cancers (BCs) contain HER2-low and HER2-zero ones. HER2-low breast cancer has been receiving wide-spread concerns as the marvelous effect of novel anti-HER2 antibody-drug conjugates, however, the characteristic remains unknown. Our aim was to explore the differences of clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. We retrospectively analyzed 501 invasive breast cancer patients with complete data on HER2 status from 2017 to 2021 in our single center, of whom 415 HER2 negative patients were included for subsequent analysis. Each cohort was further divided into hormone receptor (HR) positive and HR negative subgroup. Clinicopathological factors and survival outcomes were collected and compared between HER2-low BCs and HER2-0 BCs. HER2-low BCs was obviously higher in HR positive BCs, with 277 (90.5%) HER2-low HR positive patients, 29 (9.5%) HER2-low HR negative patients, 68 (62.4%) HER2-0 HR positive patients and 41 (37.6%) HER2-0 HR negative patients (P < 0.001). Significant differences between HER2-low BCs and Her2-0 BCs were observed in lymph node ratio (LNR) (mean rank, 215 vs. 188 P = 0.014), estrogen receptor (ER)expression (90.5% vs. 62.4% P < 0.001), progesterone receptor (PR) expression (84.3% vs. 56.9% P < 0.001), Ki-67 expression (46.4% vs. 61.5% P < 0.001), androgen receptor (AR) expression (68% vs. 50.5% P < 0.001), adjuvant chemotherapy (69% vs. 79.8% P = 0.03). HER2-low BCs had lower histological grade than HER2-0 BCs, with grade I-II (68.7% vs. 43.1%) and grade III (22.2% vs. 43.1%) P < 0.01. No statistical differences were detected between the two groups for DFS and DDFS. Our results demonstrated that HR and AR status was closely related to HER2-low breast cancers. Further exploration about survival prognosis of HER2-low breast cancer is badly needed.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chat of selecting patients in the study.
Figure 2
Figure 2
Survival outcomes of HER2-low and HER2-0 BCs.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: From the bench to the bedside. J. Exp. Clin. Cancer Res. 2022;41:310. doi: 10.1186/s13046-022-02515-x. - DOI - PMC - PubMed
    1. Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: The upgraded role of HER-3 and HER-4. Int. J. Biochem. Cell Biol. 2007;39:851–856. doi: 10.1016/j.biocel.2006.11.017. - DOI - PubMed
    1. Marchio C, et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin. Cancer Biol. 2021;72:123–135. doi: 10.1016/j.semcancer.2020.02.016. - DOI - PubMed
    1. Karamouzis MV, et al. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int. J. Cancer. 2002;102:86–90. doi: 10.1002/ijc.10654. - DOI - PubMed

Publication types